You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed disease

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)

Recruiting
  • CD20-positive Non-Hodgkin Lymphoma
  • EX103 injection
  • Zhengzhou, Henan, China
  • +3 more
Aug 28, 2023

Hodgkin Lymphoma Trial (favezelimab/pembrolizumab, bendamustine, gemcitabine)

Not yet recruiting
  • Hodgkin Lymphoma
  • favezelimab/pembrolizumab
  • +2 more
  • (no location specified)
Aug 18, 2022

Classical Hodgkin Lymphoma Trial in Philadelphia (Itacitinib, Everolimus)

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Nov 28, 2022

Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)

Recruiting
  • Lymphoma
  • +7 more
  • ATLCAR.CD30 cells
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022

Lymphoma, Non-Hodgkin, Hodgkin Lymphoma Trial in Worldwide (AZD3470)

Not yet recruiting
  • Lymphoma
  • +2 more
  • Miami, Florida
  • +10 more
Nov 13, 2023

Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)

Terminated
  • Hodgkin's Lymphoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 22, 2022

High-Risk Neuroblastoma Trial in Krakow (Chemoimmunotherapy (Dinutuximab beta in combination with chemo))

Recruiting
  • High-Risk Neuroblastoma
  • Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)
  • Krakow, Malopolska, Poland
    University Children Hospital
Mar 8, 2022

Hodgkin Lymphoma, DLBCL Trial run by the NCI (campath, Rituximab, EPOCH)

Completed
Has Results
  • Hodgkin Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Campath
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 11, 2022

Hematological Malignancies Trial in Guangzhou, Tianjin (Nemtabrutinib)

Recruiting
  • Hematological Malignancies
  • Guangzhou, Guangdong, China
  • +2 more
Aug 10, 2022

Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Relapsed Classical Hodgkin Lymphoma Trial in Stanford (Magrolimab, Pembrolizumab,

Recruiting
  • Hodgkin Lymphoma
  • +3 more
  • Stanford, California
    Stanford University
Jun 21, 2022

Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease, Mast Cell Leukemia Trial

Completed
  • Aggressive Systemic Mastocytosis
  • +3 more
  • Stanford, California
  • +10 more
Jan 12, 2023

Multiple Myeloma, Multiple Myeloma in Relapse, Tumors Trial (Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • +8 more
  • Belantamab Mafodotin-Blmf
  • +3 more
  • (no location specified)
Oct 13, 2022

Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma Trial (ANV419, Lenalidomide with low-dose dexamethasone,

Not yet recruiting
  • Multiple Myeloma
  • +4 more
  • (no location specified)
Nov 29, 2022

Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase

Recruiting
  • Lymphoblastic Leukemia
  • +4 more
  • Phase I
  • Phase II
  • Singapore, Singapore
    KK Women's and Children's hospital
Jun 20, 2022

Hodgkin Lymphoma Trial (Gemcitabine, Dexamethasone, Cisplatin)

Not yet recruiting
  • Hodgkin Lymphoma
  • (no location specified)
May 9, 2022

Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma Trial in Guangzhou (PD-1 inhibitor, PD-1

Recruiting
  • Classical Hodgkin Lymphoma
  • Refractory or Relapsed Classical Hodgkin Lymphoma
  • PD-1 inhibitor
  • PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
  • Guangzhou, Guangdong, China
  • +2 more
May 6, 2022

Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute Trial in Boston (radiation, drug, biological,

Recruiting
  • Stem Cell Transplant Complications
  • +4 more
  • Radiation
  • +7 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 19, 2023

Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory Trial in United States (CD30.CAR-T, Fludarabine,

Active, not recruiting
  • Hodgkin Lymphoma, Adult
  • +3 more
  • Duarte, California
  • +4 more
Apr 3, 2022

Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)

Not yet recruiting
  • Lymphoma, Mantle-Cell
  • +7 more
  • (no location specified)
Jun 21, 2022

Hodgkin Lymphoma Trial in New York (Mocetinostat Plus Brentuximab Vedotin)

Completed
Has Results
  • Hodgkin Lymphoma
  • Mocetinostat Plus Brentuximab Vedotin
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 10, 2022

Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia Trial in

Not yet recruiting
  • Lymphoblastic Leukemia, Acute, Childhood
  • +3 more
  • Olverembatinib, APG-2575, Dexamethasone
  • Hefei, Anhui, China
  • +3 more
Aug 8, 2022

Relapsed Pediatric ALL, Acute GVHD (Gvhd) Grade IV (Diagnosis), Relapsed Pediatric AML Trial (In Vitro T cells depletion using

Recruiting
  • Relapsed Pediatric ALL
  • +2 more
  • In Vitro T cells depletion using CliniMCAS system
  • Shanghai, China
    Shanghai Children's Medical Center
Sep 28, 2022

Hodgkin Lymphoma Trial in Saint Petersburg (Prolgolimab, Combination with prolgolimab and bendamustine)

Recruiting
  • Hodgkin Lymphoma
  • Saint Petersburg, Russian Federation
  • +1 more
Mar 3, 2023

Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD) Trial in Baltimore (BLINCYTO (Blinatumomab))

Recruiting
  • Mixed Phenotype Acute Leukemia (MPAL)
  • Measurable Residual Disease (MRD)
  • BLINCYTO (Blinatumomab)
  • Baltimore, Maryland
    Greenebaum Cancer Center at University of Maryland Medical Cente
Apr 18, 2022

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)

Recruiting
  • Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
  • Classical Hodgkin Lymphoma
  • CD30.CAR-EBVST cells
  • Houston, Texas
  • +1 more
Jul 20, 2022